EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Evaluation of the efficacy of convalescent plasma in moderate to severe COVID-19 during 2020-2021: a retrospective observational study

Sunny Kumar iD, Saurabh Mehra iD, Mrinal Sircar iD, Onkar Jha iD, Rajesh Gupta iD, Seema Sinha iD, Ravneet Kaur iD

Monaldi Archives for Chest Disease · 2024

DOI: 10.4081/monaldi.2024.3050 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Monaldi Archives for Chest Disease, 2024. Verfasst von Sunny Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology and Critical Care, Fortis Hospital, Noida, Uttar Pradesh. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Convalescent plasma therapy (CPT) is one of the treatment modalities used for COVID-19. Initial smaller studies showed the usefulness of CPT in COVID-19, but larger studies showed that it is not effective. This is a retrospective observational study conducted between 1st June 2020 and 31st July 2021 at a tertiary hospital in Noida, India. Our analysis was done on 213 COVID-19 patients, comprising 170 cases who were given convalescent plasma and 43 controls who did not get CPT. Outcomes analyzed were improvement in PaO2:FiO2 ratio (PFR) by day 5 of CPT, 28-day mortality, and level of inflammatory markers. Mean PFR before plasma transfusion was comparable between CPT and control groups (142.11±73.99 vs. 151.11±88.87, p=0.56). There was no significant difference in mean PFR after 5 days of CPT between cases and the control group (187.02±102.34 vs. 160.29±83.39, p=0.206). 28-day mortality was 47.05% in the CPT group and 37.20% in the control group (p=0.246). Mortality among the subgroup of patients on invasive mechanical ventilation was 89.74% in cases and 80% in controls (p=0.518). No significant difference was found in levels of serum ferritin, interleukin-6, and C-reactive protein between the two groups. Convalescent plasma does not have a significant effect on day 5 PFR and 28-day mortality. Our study could not find any subgroup of patients who would benefit from CPT. This study reinforces that CPT does not benefit moderate to severe patients with COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansRetrospective StudiesMaleFemaleCOVID-19 SerotherapyMiddle AgedImmunization, PassiveIndiaTreatment OutcomeSARS-CoV-2Severity of Illness IndexAdultAgedC-Reactive Protein

Stichwörter der Autor:innen

COVID-19Convalescent plasma therapyPaO2:FiO2 ratiomortalityretrospective study

Substanzen

C-Reactive Protein

Autor:innen und Institutionen

  • Department of Pulmonology and Critical Care, Fortis Hospital, Noida, Uttar Pradesh.
  • Department of Pulmonary Medicine, Paras HEC Hospital, Ranchi.
  • Department of Pulmonology and Critical Care, Fortis Hospital, Greater Noida, Uttar Pradesh.
  • Department of Transfusion Medicine, Fortis Hospital, Noida, Uttar Pradesh.
  • Lab Operations and Microbiology, Agilus Diagnostics, Fortis Hospital, Noida, Uttar Pradesh.

ORCID-Profile: Sunny Kumar, Saurabh Mehra, Mrinal Sircar, Onkar Jha, Rajesh Gupta, Seema Sinha, Ravneet Kaur

Zitieren

APA

Kumar, S., Mehra, S., Sircar, M., Jha, O., Gupta, R., Sinha, S., & Kaur, R. (2024). Evaluation of the efficacy of convalescent plasma in moderate to severe COVID-19 during 2020-2021: a retrospective observational study. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2024.3050

Vancouver

Kumar S, Mehra S, Sircar M, Jha O, Gupta R, Sinha S, et al. Evaluation of the efficacy of convalescent plasma in moderate to severe COVID-19 during 2020-2021: a retrospective observational study. Monaldi Archives for Chest Disease. 2024. doi:10.4081/monaldi.2024.3050

BibTeX
@article{Kumar2024,
  author = {Kumar, Sunny and Mehra, Saurabh and Sircar, Mrinal and Jha, Onkar and Gupta, Rajesh and Sinha, Seema and Kaur, Ravneet},
  title = {Evaluation of the efficacy of convalescent plasma in moderate to severe COVID-19 during 2020-2021: a retrospective observational study},
  journal = {Monaldi Archives for Chest Disease},
  year = {2024},
  doi = {10.4081/monaldi.2024.3050}
}
Kostenlos starten →